Weekly Rundown: Key Catalysts for Small-Cap Stocks (September 22–26)

From recent disclosures to corporate shifts, we’ve highlighted the top small-cap catalysts to watch. Here’s your weekly preview (September 22–26).

--

Weekly Catalyst Breakdown:

DVLT: Nathaniel Bradley, CEO of Datavault AI, will present and exhibit the company’s technologies at the XRP Seoul 2025 Conference on September 22 in Seoul, South Korea, one of the world’s largest technology and innovation events.

AREC: The company will attend multiple events including Rare Earth Mines, Magnets & Motors 2025 in Toronto (Sept 22–24), the U.S.-Africa Critical Minerals Roundtable in New York (Sept 22), the Nasdaq Building the Future Summit in New York (Sept 22), and the Strength Through Innovation Summit in Reston, VA (Sept 23–24), with executives presenting, speaking on panels, and engaging in investor meetings.

BNAI: At the Swiss Life Network Partners Conference in London (Sept 23–25), the company will showcase a new AI Agent for insurance workflows, developed in collaboration with Swiss Life, marking a milestone in enterprise-scale insurance technology.

DAIO: The company will participate in SMT Worldwide Tech Days in Barcelona, Spain (Sept 23–25), showcasing its solutions alongside channel partner SMT Worldwide.

PMEC: Primech will showcase its HYTRON robot at CMS Berlin (Sept 23–26) as part of a global debut tour, giving industry professionals and potential partners the chance to experience the technology firsthand.

RCT: Justin Floyd, CEO and Co-Founder, will speak at the Roth AI Summit on Sept 24, outlining the company’s mission to transform the $14.6T FMCG market by addressing the $2T “inventory gap” caused by outdated systems and inefficiencies.

SNTI: Kanya Rajangam, M.D., Ph.D., President and CMO, will present at the MedInvest Biotech & Pharma Conference in Palo Alto, CA, on Sept 24 at 9:55 AM PT.

BNZI: Founder & CEO Joe Davy will present at the Emerging Growth Conference on Sept 24.

NB: Mark A. Smith, CEO of NioCorp Developments, will appear on Fox Business’ “Mornings with Maria” on Sept 22 at 6:30 AM ET.

CLRB: The company will deliver multiple presentations on Sept 24 at a TRP Supply Chain & Manufacturing event covering isotope supply, facility downtime, and radiotherapeutic half-life, and will also present pediatric glioma interim trial data at AACR’s Special Conference on Pediatric Cancer (Sept 26, 2:50 PM ET).

IMUX: At the 41st Congress of ECTRIMS in Barcelona (Sept 24–26), Immunic will present new data on vidofludimus calcium (IMU-838) across one oral and multiple poster sessions, including a Phase 2 CALLIPER trial readout.

OCGN: CEO Dr. Shankar Musunuri will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York (Sept 8–10) and in a spotlight FDA strategy panel at Biotech on Tap 2025 in Munich (Sept 24–26).

BANL: The company will present live at the Emerging Growth Conference on Sept 24 at 1:10 PM ET during a 30-minute session.

LCUT: Lifetime Brands executives Robert Kay (CEO) and Laurence Winoker (CFO) will host a fireside chat at the MicroCap Rodeo Conference in NYC on Sept 25 at 9:30 AM ET and will also hold one-on-one investor meetings.

PHIO: CEO Robert Bitterman will provide updates on the Phase 1b trial for skin cancer (PH-762) and discuss strategy at an investor conference (Sept 25–26), with management also available for one-on-one meetings.

NWTG: The company has been named an Official Partner of World Long Drive 2025, with its Motion Series shafts to feature throughout the season and culminating at the World Championships (Sept 25–27, La Salle, CO).

PSQH: The company will host a virtual analyst and investor day on Sept 25 from 11 AM–1 PM ET, where CEO Michael Siefert and executives will outline fintech initiatives, digital asset plans, and long-term strategy.

DEFT: The company will launch its inaugural Insights Symposium in Frankfurt on Sept 25, fostering discussions on the convergence of decentralized and traditional finance among investors, regulators, and thought leaders.

OMER: FDA’s PDUFA target action date for narsoplimab in TA-TMA is Sept 25, marking a key regulatory decision for the company.

DRTS: The company will attend the Radiopharma Landscape Conference in New York on Sept 26, participating in one-on-one meetings with investors.

LUCY: The company will exhibit at SILMO Paris (Sept 26–29), one of the world’s largest optics and eyewear trade shows, showcasing new technologies and engaging with global industry leaders.

RGP: CEO Kate Duchene, COO Bhadresh Patel, and CFO Jennifer Ryu will participate in a virtual fireside chat at William Blair’s Human Capital Services Conference on Sept 24 at 11:00 AM CT and will host investor meetings.

IINN: The company will debut its HYLA blood sensor at the U.S. ELSO Annual Conference in Washington, D.C. (Sept 27–30), presenting to thousands of global clinicians and researchers.

INBS: Following an FDA request for additional information on its Intelligent Fingerprinting Drug Screening System, INBS expects to provide an investor update in the next 10 days outlining an updated timeline for FDA clearance, with the estimated timeline around Sept 27.

CADL: CAN-2409 Phase 3 trial data in localized prostate cancer will be presented at ASTRO’s Annual Meeting in San Francisco on Sept 28, with inclusion in the Science Highlights session recognizing top research.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.